- Home
- IBIO vs AEON Comparison
IBIO vs AEON Comparison
Compare IBIO & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- AEON
- Stock Information
- Founded
- IBIO 2008
- AEON N/A
- Country
- IBIO United States
- AEON United States
- Employees
- IBIO N/A
- AEON N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- AEON Health Care
- Exchange
- IBIO Nasdaq
- AEON Nasdaq
- Market Cap
- IBIO 24.3M
- AEON 21.6M
- IPO Year
- IBIO N/A
- AEON N/A
- Fundamental
- Price
- IBIO $2.83
- AEON $0.15
- Analyst Decision
- IBIO Strong Buy
- AEON Strong Buy
- Analyst Count
- IBIO 3
- AEON 1
- Target Price
- IBIO $4.87
- AEON $5.00
- AVG Volume (30 Days)
- IBIO 132.6K
- AEON 45.9M
- Earning Date
- IBIO 02-07-2025
- AEON 11-13-2024
- Dividend Yield
- IBIO N/A
- AEON N/A
- EPS Growth
- IBIO N/A
- AEON N/A
- EPS
- IBIO N/A
- AEON 0.34
- Revenue
- IBIO $175,000.00
- AEON N/A
- Revenue This Year
- IBIO N/A
- AEON N/A
- Revenue Next Year
- IBIO N/A
- AEON N/A
- P/E Ratio
- IBIO N/A
- AEON $0.45
- Revenue Growth
- IBIO 250.00
- AEON N/A
- 52 Week Low
- IBIO $1.02
- AEON $0.10
- 52 Week High
- IBIO $4.98
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- IBIO 61.21
- AEON 27.61
- Support Level
- IBIO $2.40
- AEON $0.10
- Resistance Level
- IBIO $2.93
- AEON $0.22
- Average True Range (ATR)
- IBIO 0.19
- AEON 0.05
- MACD
- IBIO 0.04
- AEON -0.02
- Stochastic Oscillator
- IBIO 83.87
- AEON 10.04
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.